The optimal treatment strategy for T4 NSCLC that presents as a primary tumor with
additional pulmonary nodules in an ipsilateral lobe is not well characterized. While
current National Comprehensive Cancer Network (NCCN) guidelines suggest surgical resection
for N0 or N1 disease, the recommended treatment for N2 disease is chemoradiation therapy
without surgery. Few studies with limited sample sizes, however, have assessed the
use of surgery for patients with T4, N2 (Stage IIIB) NSCLC. This study evaluated long-term
survival of patients with T4, N2 NSCLC who received multimodal therapy including surgery
as compared with patients who received chemoradiation alone.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Thoracic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
